Skip to main content

ABCL research · 13F holders by reporting quarter

AbCellera Biologics Inc. (ABCL): 13F holders, 2026Q1

The largest share positions in ABCL that the managers Kresmion follows reported on Form 13F for 2026Q1, as filed. The current quarter, the company's SEC filings and its recent events are on the ABCL research page.

ABCL positions held by the managers we follow (2026Q1)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported valueQoQ
TWO SIGMA INVESTMENTS, LP FundCUSIP 00288U106 · 2026Q1$36.9M0.03%+81.8%
RENAISSANCE TECHNOLOGIES LLC FundCUSIP 00288U106 · 2026Q1$5.3M0.01%-36.8%
CITADEL ADVISORS LLC FundCUSIP 00288U106 · 2026Q1$4.8M0.00%n/a
MILLENNIUM MANAGEMENT LLC FundCUSIP 00288U106 · 2026Q1$4.5M0.00%-27.0%
Point72 Asset Management, L.P. FundCUSIP 00288U106 · 2026Q1$4M0.01%+17.7%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.